GOZETOTIDE

DRUG3 trials

Sponsors

Cliniques Universitaires Saint-Luc, Novartis Pharma AG

Conditions

Metastatic castration resistant prostate cancer (mCRPC)PSMA-positive mCRPC with prior exposure to at least one prior ARPImetastatic clear cell Renal Carcinoma Cell

Phase 1

A phase Ib/II open-label, multi-center study of the DNA protein kinase inhibitor AMO959 with lutetium (177Lu) vipivotide tetraxetan (AAA617) in combination with an androgen receptor pathway inhibitor (ARPI) in adult participants with PSMA-positive metastatic castration resistant prostate cancer (mCRPC)

Not yet recruitingCTIS2025-521859-23-00

Novartis Pharma AGPSMA-positive mCRPC with prior exposure to at least one prior ARPI

Target: 61Updated: 2026-03-06

Phase 2

Multicentric trial evaluating the correlation between early PSMA-PET change and response to systemic treatment for first-line metastatic clear cell Renal Carcinoma Cell.

Not yet recruitingCTIS2024-517098-26-00

Cliniques Universitaires Saint-Lucmetastatic clear cell Renal Carcinoma Cell

Target: 75Updated: 2025-08-22

A Phase II, randomized, open-label, multi-center study of JSB462 in combination with lutetium (177Lu) vipivotide tetraxetan in adult male patients with PSMA-positive metastatic castration resistant prostate cancer (mCRPC)

RecruitingCTIS2024-520155-24-00

Novartis Pharma AGMetastatic castration resistant prostate cancer (mCRPC)

Start: 2025-10-16Target: 46Updated: 2026-01-26